SCHEMBL720043

SCHEMBL720043

Cc1cnc(Nc2nc(-c3ccccc3)nc3ccccc23)s1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 3/20 1.00
GSK3B P49841 3/20 1.00
ABCG2 Q9UNQ0 10/20 0.58
MAPT P10636 2/20 0.58
LMNA P02545 1/20 0.58
TP53 P04637 1/20 0.58
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
PDE5A O76074 5/20 0.56
ABCB1 P08183 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
TGFBR1 P36897 1/20 0.52
MAPK14 Q16539 1/20 0.52
AURKA O14965 1/20 0.52
SRC P12931 1/20 0.52
EIF2AK2 P19525 1/20 0.52
AURKB Q96GD4 1/20 0.52
ACP1 P24666 2/20 0.51
GAA P10253 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1083769 0.81 GSK3A (0.68) GSK3AGSK3BABCG2MAPTLMNA
SCHEMBL166294 0.76 GSK3A (0.60) GSK3AGSK3BABCG2MEN1KMT2A
SCHEMBL166293 0.76 GSK3A (0.60) GSK3AGSK3BABCG2MEN1KMT2A
SCHEMBL165180 0.76 GSK3A (0.60) GSK3AGSK3BABCG2MEN1KMT2A
SCHEMBL255871 0.76 GSK3A (0.60) GSK3AGSK3BABCG2MEN1KMT2A
SCHEMBL5252846 0.76 GSK3A (0.61) GSK3AGSK3BABCG2MAPTLMNA
SCHEMBL1063103 0.74 ABCG2 (1.00) ABCG2MAPTLMNATP53MEN1
SCHEMBL4891835 0.73 ABCG2 (0.69) ABCG2MAPTLMNATP53MEN1
SCHEMBL8095812 0.73 ABCG2 (1.00) ABCG2MAPTLMNATP53MEN1
SCHEMBL1063009 0.73 ABCG2 (0.69) GSK3AGSK3BABCG2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124392-B2 Crystal structure of Aurora-2 protein and binding pockets thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-28 US claimed
EP-1549318-B1 CRYSTAL STRUCTURE OF AURORA-2 PROTEIN AND BINDING POCKETS THEREOF VERTEX PHARMA (US) 2010-02-17 EP claimed
US-7361492-B2 for computer aided drug design and drug screening for inhibitors of this cancer-related serine/threonine kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-04-22 US claimed
EP-1549318-A4 CRYSTAL STRUCTURE OF AURORA-2 PROTEIN AND BINDING POCKETS THEREOF VERTEX PHARMA (US) 2006-03-08 EP claimed
EP-1549318-A2 CRYSTAL STRUCTURE OF AURORA-2 PROTEIN AND BINDING POCKETS THEREOF Vertex Pharmaceuticals Incorporated (US) 2005-07-06 EP claimed
US-20050143402-A1 Crystal structure of aurora-2 protein and binding pockets thereof VERTEX PHARMACEUTICALS INCORPORATED 2005-06-30 US claimed
WO-2003092607-A2 CRYSTAL STRUCTURE OF AURORA-2 PROTEIN AND BINDING POCKETS THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2003-11-13 WO claimed
US-8124392-B2 Crystal structure of Aurora-2 protein and binding pockets thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-28 US disclosed
US-20110104782-A1 CRYSTAL STRUCTURE OF AURORA-2 PROTEIN AND BINDING POCKETS THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-05-05 US disclosed
US-7809541-B2 Crystal structure of aurora-2 protein and binding pockets thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-05 US disclosed
EP-1549318-B1 CRYSTAL STRUCTURE OF AURORA-2 PROTEIN AND BINDING POCKETS THEREOF VERTEX PHARMA (US) 2010-02-17 EP disclosed
US-20090287422-A1 Crystal structure of aurora-2 protein and binding pockets thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-19 US disclosed
US-7361492-B2 for computer aided drug design and drug screening for inhibitors of this cancer-related serine/threonine kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-04-22 US disclosed
EP-1549318-A2 CRYSTAL STRUCTURE OF AURORA-2 PROTEIN AND BINDING POCKETS THEREOF Vertex Pharmaceuticals Incorporated (US) 2005-07-06 EP disclosed
US-20050143402-A1 Crystal structure of aurora-2 protein and binding pockets thereof VERTEX PHARMACEUTICALS INCORPORATED 2005-06-30 US disclosed
US-6846928-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-01-25 US disclosed
EP-1485376-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES Vertex Pharmaceuticals Incorporated (US) 2004-12-15 EP disclosed
US-20030225073-A1 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2003-12-04 US disclosed
WO-2003092607-A2 CRYSTAL STRUCTURE OF AURORA-2 PROTEIN AND BINDING POCKETS THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2003-11-13 WO disclosed
WO-2003078423-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS, INC. (US) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225073-A1 Compositions useful as inhibitors of protein kinases MAP3K20, PACSIN2, MAP3K1 GSK3A 263/4885GSK3B 312/4885ABCG2 2455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.